Paul Brannelly joined Collegium Pharmaceutical in February 2015 as Executive Vice President and Chief Financial Officer. Prior to joining Collegium, Mr. Brannelly most recently served as Senior Vice President, Finance & Administration and Treasurer of Karyopharm Therapeutics Inc., a publicly traded, clinical-stage pharmaceutical company. Prior to Karyopharm, he served as Vice President Finance, Treasurer and Secretary for Verastem, Incorporated, a publicly traded biotechnology company. Earlier in his career, Mr. Brannelly was Chief Financial Officer of Longwood Fund, a healthcare dedicated venture capital fund, and also held senior financial management roles with Sirtris Pharmaceuticals (acquired by GlaxoSmithKline), CombinatoRx and Dyax. With more than 20 years in the biopharmaceutical industry, Mr. Brannelly has raised $1.0 billion in public and private capital. He holds a Bachelors in Business Administration in Accounting from the University of Massachusetts, Amherst and was a Certified Public Accountant.